Department of Public Health and Policy, University of Liverpool, Liverpool, UK.
Division of Cardiology, University of British Columbia, Vancouver, Canada.
BMJ Open. 2015 Jan 22;5(1):e006070. doi: 10.1136/bmjopen-2014-006070.
To analyse the falls in coronary heart disease (CHD) mortality in England between 2000 and 2007 and quantify the relative contributions from preventive medications and population-wide changes in blood pressure (BP) and cholesterol levels, particularly by exploring socioeconomic inequalities.
A modelling study.
Sources of data included controlled trials and meta-analyses, national surveys and official statistics.
English population aged 25+ in 2000-2007.
Number of deaths prevented or postponed (DPPs) in 2007 by socioeconomic status. We used the IMPACTSEC model which applies the relative risk reduction quantified in previous randomised controlled trials and meta-analyses to partition the mortality reduction among specific treatments and risk factor changes.
Between 2000 and 2007, approximately 20 400 DPPs were attributable to reductions in BP and cholesterol in the English population. The substantial decline in BP was responsible for approximately 13 000 DPPs. Approximately 1800 DPPs came from medications and some 11 200 DPPs from population-wide changes. Reduction in population BP prevented almost twofold more deaths in the most deprived quintile compared with the most affluent. Reduction in cholesterol resulted in approximately 7400 DPPs; approximately 5300 DPPs were attributable to statin use and approximately 2100 DPPs to population-wide changes. Statins prevented almost 50% more deaths in the most affluent quintile compared with the most deprived. Conversely, population-wide changes in cholesterol prevented threefold more deaths in the most deprived quintile compared with the most affluent.
Population-wide secular changes in systolic blood pressure (SBP) and cholesterol levels helped to substantially reduce CHD mortality and the associated socioeconomic disparities. Mortality reductions were, in absolute terms, greatest in the most deprived quintiles, mainly reflecting their bigger initial burden of disease. Statins for high-risk individuals also made an important contribution but maintained socioeconomic inequalities. Our results strengthen the case for greater emphasis on preventive approaches, particularly population-based policies to reduce SBP and cholesterol.
分析 2000 年至 2007 年英格兰冠心病死亡率下降情况,并量化预防药物和血压(BP)及胆固醇水平的普遍变化的相对贡献,特别是通过探索社会经济不平等现象。
建模研究。
数据来源包括对照试验和荟萃分析、全国性调查和官方统计数据。
2000-2007 年 25 岁以上的英国居民。
2007 年按社会经济地位划分的预防或推迟死亡人数(DPP)。我们使用了 IMPACTSEC 模型,该模型将以前随机对照试验和荟萃分析量化的相对风险降低应用于特定治疗和危险因素变化的死亡率降低。
2000 年至 2007 年间,英格兰人口中 BP 和胆固醇降低导致约 20400 例 DPP。BP 的大幅下降导致约 13000 例 DPP。约 1800 例 DPP 来自药物,约 11200 例 DPP 来自人群变化。与最富裕的五分位数相比,最贫困的五分位数中,人群 BP 降低导致的死亡人数减少了近两倍。胆固醇降低导致约 7400 例 DPP;约 5300 例 DPP 归因于他汀类药物的使用,约 2100 例 DPP 归因于人群变化。与最贫困的五分位数相比,最富裕的五分位数中他汀类药物导致的死亡人数减少了近 50%。相反,与最富裕的五分位数相比,最贫困的五分位数中人群胆固醇变化导致的死亡人数增加了三倍。
收缩压(SBP)和胆固醇水平的人群整体变化有助于大大降低冠心病死亡率和相关的社会经济差异。从绝对值来看,死亡率的降低在最贫困的五分位数中最大,主要反映了他们最初更大的疾病负担。高危人群使用他汀类药物也做出了重要贡献,但维持了社会经济不平等。我们的研究结果进一步证实,需要更加重视预防方法,特别是以降低 SBP 和胆固醇为目标的人群为基础的政策。